Clinical trials for trastuzumab biosimilars - GaBI Journal
![PDF] Clinical trials of Herceptin(trastuzumab). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4d6467fad15262096d78d0838ef39414b4b4d90a/2-Table1-1.png "PDF] Clinical trials of Herceptin(trastuzumab). | Semantic Scholar")
PDF] Clinical trials of Herceptin(trastuzumab). | Semantic Scholar
Frontiers | A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer | Oncology
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study - ESMO Open
Table 2 from Phase I and II clinical trials of trastuzumab. | Semantic Scholar
Treatment groups, interventions and efficacy parameters of the clinical... | Download Table
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial - The Lancet Oncology
Clinical trials for trastuzumab biosimilars - GaBI Journal
PERJETA® (pertuzumab) Neoadjuvant Trial Design | HCP
/herceptin-biologic-therapy-for-breast-cancer-430573-FINAL2-ace372d34fd544149e92f294c2c22958.png "Herceptin Therapy for Breast Cancer")
Herceptin Therapy for Breast Cancer
Landmark clinical trials of palliative trastuzumab in breast cancer. | Download Table
Schema of the APHINITY clinical trial evaluating efficacy of adjuvant... | Download Scientific Diagram
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial - Clinical Breast Cancer
Optimizing the Duration of Trastuzumab: A Fresh Perspective
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? | npj Breast Cancer
Pharmaceuticals | Free Full-Text | Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study | HTML
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer
